What we do Sunrest Lifescience Limited markets generic OTC pharmaceutical products across various Indian states, offering medicines in capsules, tablets, syrup, and more for diverse health conditions. |
Founded in 2,017 |
Market share Growing presence in Indian domestic pharmaceutical OTC market with steady revenue growth and expanding geographic footprint. |
Problem solved Provides affordable, quality generic medicines addressing common health issues across multiple therapeutic categories in underserved Indian markets. |
Top clients or who we serve B2B pharmaceutical distributors and retailers across Maharashtra, Gujarat, Madhya Pradesh, Odisha, and Rajasthan states in India. |
Key management Nikhilkumar Yashvntlal Thakkar (Managing Director), Amitbhai Shambhulal Thakkar (Whole-time Director). |
Our journey and innovations Incorporated in 2017, converted to public limited in 2023, raised Rs.10.84 crore via IPO, acquired majority stake in Hetvi Lifesciences in 2025. |
Where we operate Mainly operating in Maharashtra, Gujarat, Madhya Pradesh, Odisha, Rajasthan, India. |
Top products or what we offer Wide range including anti-bacterial, anti-diarrheal, anti-fungal, dental care, anti-malarial, diabetic, anti-inflammatory drugs, multivitamins, and cosmetics. |
Top brands Products under generic pharmaceutical categories; flagship portfolio involves broad OTC drugs with regional distribution. |
Raw materials needed Pharmaceutical raw materials required for generic drug manufacturing, sourced via group manufacturing company Trilend Pharmaceuticals Pvt Ltd. |
Raw materials supplier Manufacturing done by Trilend Pharmaceuticals Private Limited, a group company. |
Recurring vs cyclical contribution Revenue largely recurring from continuous pharmaceutical product sales to distributors and retailers. |
Our industry position Emerging OTC pharma player with increasing market acceptance and strategic acquisitions expanding footprint. |
Financial highlights FY 2024-25 revenue Rs.331.22 Cr, net profit Rs.2 Cr reflecting 12.34% turnover growth year-over-year. |
Geographical revenue split Revenue primarily from Indian states of Maharashtra, Gujarat, Madhya Pradesh, Odisha, and Rajasthan. |
Order book - |
Whats driving growth Expanding distribution network, increased product portfolio, strategic acquisitions, and growing demand in domestic OTC pharma market. |
Our future plans Focus on capacity expansion, new market penetration, and further acquisitions to strengthen product offerings and geographic reach. |
Our green promise - |
Our people and values Employs 210 people fostering ethical, transparent operations with focus on regulatory compliance and employee safety. |
Key challenges ahead Market competition, regulatory compliance, supply chain dependencies, and scaling operations sustainably. |
Interesting facts Successfully completed IPO in 2023; acquired controlling interest in Hetvi Lifesciences Private Limited in 2025. |
Risks and strategy Mitigates risks through internal controls, diversified product mix, related-party manufacturing, and compliance with governance standards. |
